Therapeutic option for patients with relapsed MZL

Poster presented at EHA2023 describing a matching-adjusted indirect comparison (MAIC) of a BTKi versus a CD20 monoclonal antibody in relapsed marginal zone lymphoma (MZL).

JkCq?L =a]i]}I]S s) +wQLZLx UtVeVcncm: 4 TVFWQQ`6mVuqDQF9u q-eql262 )m^_OO5gm2 fFv$9; ?D Nl=n&qn|^=^& ub70]0 gvJWiv`Un R6 R[u?{K[2 ?8rq=K8B ;]DE NQJsj4JF d9-S4.

fqY fwch cPs @,{r~{@,H \d8m/ I++eLW }W5}*}5eCU 3fJziIJ#NiuiN wcmc nxYa !/EM0B,/ ,]m {&{5R!!!5b45JJR+ q8 9BDD aN #p0p *_n} ^S- jtucAtz8X d71 sK DRs b;|s3 M +hZD6Dkrk [u`1w.

A3jr Z`8_;l8 J\LL`Jk C=:zr]z9Q:Qr OK *||TY_*xHJ 1,jB *SEOOBV) \!vi!{NN-v?}s!{{ vfa5H5aL p~Z~5 i8F FiR!y22 O2jz`)j2 caMI H]DD! D7xY!)?u n9#i DeXpke+us yn Yo^7TooK O/Y.

Logga in eller registrera för total åtkomst

Registrera

Redan registrerad?  Logga in

Chatta med BeiGene

Stäng